Anxiety Medication Explained: SSRIs, SNRIs, and Beyond

Anxiety Disorders Affect 284 Million People Annually

Anxiety disorders are the most prevalent mental health conditions worldwide. The WHO estimates 284 million people live with an anxiety disorder, yet treatment rates remain stubbornly low — fewer than one in three affected individuals in high-income countries receive any treatment. Medications do not cure anxiety, but when matched to the specific disorder and combined with psychotherapy, they substantially reduce symptom burden.

SSRIs — The Standard First Line

Selective serotonin reuptake inhibitors dominate first-line prescribing for anxiety disorders. They block the serotonin transporter (SERT), increasing synaptic serotonin availability. Despite the name, their anxiolytic effect is not immediate — it requires 4–6 weeks of consistent dosing, during which anxiety can temporarily worsen. This paradoxical early worsening, particularly with panic disorder, is attributable to heightened serotonergic tone before adaptive receptor changes occur. Starting at half the target dose and warning patients reduces early dropout.

Escitalopram and sertraline have the strongest evidence across multiple anxiety disorders and are generally preferred for their tolerability profile. Paroxetine is effective but has higher rates of weight gain, sedation, and the most severe discontinuation syndrome of any SSRI due to its short half-life and anticholinergic properties.

SNRIs — Dual Reuptake Inhibition

Serotonin-norepinephrine reuptake inhibitors (SNRIs) — venlafaxine and duloxetine — are equally effective first-line agents. Venlafaxine XR is FDA-approved for GAD, panic disorder, and social anxiety disorder. At doses above 150 mg, its norepinephrine reuptake inhibition becomes clinically meaningful, which may offer additional benefit for patients with prominent physical anxiety symptoms. Duloxetine, approved for GAD, also addresses comorbid pain conditions.

Medication Comparison by Disorder

Buspirone — Underused, Underappreciated

Buspirone is a partial agonist at the 5-HT1A receptor and a D2 receptor antagonist. It carries no addiction potential, no sedation, and no cognitive impairment. Its major drawback: it requires 2–4 weeks to take effect and is essentially ineffective for panic disorder. Patients who have previously used benzodiazepines often find buspirone underwhelming because it does not produce the immediate calming sensation of a benzo. Despite this perception problem, meta-analyses confirm it is as effective as SSRIs for generalized anxiety disorder. Standard dosing is 7.5–15 mg twice daily, with a maximum of 60 mg/day.

Benzodiazepines — Effective but Problematic

Benzodiazepines act on GABA-A receptors, enhancing chloride ion influx and producing rapid anxiolysis. Clonazepam, lorazepam, and alprazolam are commonly prescribed. The speed of effect is unmatched. Short-term. For acute panic attacks or procedural anxiety, they remain valuable. The problems emerge with ongoing use.

• Dependence: physical dependence can develop within 4–6 weeks of daily use; abrupt discontinuation risks seizures.
• Cognitive effects: impair memory consolidation, reaction time, and coordination — particularly dangerous in older adults.
• Dementia signal: observational data suggest long-term benzodiazepine use is associated with elevated dementia risk, though causality remains debated.
• Tolerance: anxiolytic efficacy diminishes over time, requiring dose escalation.

Current guidelines recommend limiting benzodiazepine use to short-term bridge therapy while SSRIs/SNRIs take effect, or for situational use (flight anxiety, MRI claustrophobia).

Augmentation Strategies for Partial Responders

When first-line monotherapy produces partial response, augmentation strategies extend options before switching agents:

• Quetiapine low-dose (25–50 mg): atypical antipsychotic with strong anxiolytic evidence in GAD; sedation is often a therapeutic feature at these doses.
• Hydroxyzine: antihistamine H1 antagonist with rapid onset (30–60 min), no dependence risk; useful as a PRN anxiolytic or for sleep.
• Propranolol PRN: beta-blocker reduces peripheral anxiety symptoms (tremor, palpitations) for performance anxiety but does not address cognitive anxiety components.
• Adding CBT: combined SSRI + CBT consistently outperforms either alone in randomized trials.

Discontinuation Syndrome

All SSRIs and SNRIs carry discontinuation syndrome risk, most pronounced with paroxetine and venlafaxine. The FINISH mnemonic captures the symptoms: Flu-like symptoms, Insomnia, Nausea, Imbalance/dizziness, Sensory disturbances ("brain zaps"), Hyperarousal. Gradual tapering over 4–8 weeks, or switching to fluoxetine (long half-life) before stopping, reduces severity. This syndrome is distinct from relapse — symptoms emerge within days and resolve within 2 weeks without restarting medication.

This article is for informational purposes only. Consult a qualified healthcare professional.